Drug Trial Radar · NCT00055874
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Last checked: Nov 19, 2026Latest source record: May 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,551
Actual
Start
Jun 2002
Primary completion
Mar 31, 2012
Study completion Mar 31, 2017
Sponsor
- Lead sponsor
- Heidelberg UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 7, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, imatinib mesylate may stop the growth of cancer cells by blocking the enzymes needed for cancer cell growth. Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known which treatment regimen is most effective in treating chronic phase chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying imatinib mesylate with or without interferon alfa or cytarabine to see how well it works compared with interferon alfa followed by donor stem cell transplant in treating patients with newly diagnosed chronic phase chronic myelogenous leukemia.
Conditions
- Leukemia
Interventions
recombinant interferon alfaBiological
cytarabineDrug
hydroxyureaDrug
imatinib mesylateDrug
allogeneic bone marrow transplantationProcedure
autologous bone marrow transplantationProcedure
peripheral blood stem cell transplantationProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival
- Risk group-dependent survival
- Progression-free survival
- Hematologic, cytogenetic, and molecular response rates
Locations
66 sites in 2 countries. Site status is shown where the registry gives one.
Krankenhaus / Klinikum Krefeld
Aachen, Germany
Kreiskrankenhaus Aurich
Aurich, Germany
Kreiskrankenhaus
Bad Hersfeld, Germany
St. Hedwig Krankenhaus
Berlin, Germany
Haematologisch-Onkologische Schwerpunktpraxis
Berlin, Germany
Schwerpunktpraxis fuer Haematologie und Internistische Onkologie
Berlin, Germany
Gemeinschaftspraxis fuer Haematologie und Internistische Onkologie
Berlin, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, Germany
Augustinum
Bonn, Germany
Hamatologische Sprechstunde
Brandenburg, Germany
Praxis Dres. F.& G. Doering
Bremen, Germany
Staedtisches Kliniken Delmenhorst
Delmenhorst, Germany
Universitaetsklinikum Essen
Essen, Germany
Evangelisches Krankenhaus Essen Werden
Essen, Germany
Klinikum der J.W. Goethe Universitaet
Frankfurt, Germany
Internistische Praxisgemeinschaft
Germering, Germany
DR Herbert - Nieper Krankenhaus Goslar
Goslar, Germany
Universitaetsklinikum Goettingen
Göttingen, Germany
St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH
Hagen, Germany
Asklepios Klinik St. Georg
Hamburg, Germany
University Medical Center Hamburg - Eppendorf
Hamburg, Germany
Evangelische Krankenhaus Hamm
Hamm, Germany
Medizinische Universitaetsklinik und Poliklinik
Heidelberg, Germany
Universitatsklinikum Heidelberg
Heidelberg, Germany
Ruprecht - Karls - Universitaet Heidelberg
Heidelberg, Germany
Medical University Hospital Homburg
Homburg, Germany
Universitaetsklinikum des Saarlandes
Homburg, Germany
Westpfalz-Klinikum GmbH
Kaiserslautern, Germany
Staedtisches Klinikum Karlsruhe gGmbH
Karlsruhe, Germany
St. Vincentius - Kliniken
Karlsruhe, Germany
Klinikum Kempten Oberallgaeu
Kempten, Germany
University Hospital Schleswig-Holstein - Kiel Campus
Kiel, Germany
Klinikum Krefeld GmbH
Krefeld, Germany
Internistisches Fachaerzte Zentrum Langen
Langen, Germany
Caritas - Krakenhaus Lebach
Lebach, Germany
Onkologische Schwerpunktpraxis - Leer
Leer, Germany
Klinikum Lippe - Lemgo
Lemgo, Germany
Klinikum der Stadt Ludwigshafen am Rhein
Ludwigshafen am Rhein, Germany
III Medizinische Klinik Mannheim
Mannheim, Germany
Hospital Maria-Hilf II
Mönchengladbach, Germany
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.